Previous close | 1,150.56 |
Open | 1,150.00 |
Bid | 1,130.76 x 100 |
Ask | 1,131.84 x 100 |
Day's range | 1,128.97 - 1,152.87 |
52-week range | 769.19 - 1,211.20 |
Volume | |
Avg. volume | 457,875 |
Market cap | 124.731B |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | 29.93 |
EPS (TTM) | 37.80 |
Earnings date | 31 Oct 2024 - 04 Nov 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1,167.97 |
On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), executed a sale of 100 shares of the company at a price of $1178.69 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 17,682 shares of Regeneron Pharmaceuticals Inc.
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.